Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
31 Leser
Artikel bewerten:
(0)

Study Shows AcceleDent Reduces Pain and Discomfort During Orthodontic Treatment

Findings Published in Angle Orthodontics Show Micropulse Vibration Significantly Lowers Pain Scores

HOUSTON, March 21, 2016 /PRNewswire/ -- The results of a recently published clinical trial demonstrate that AcceleDent®, an FDA-cleared pulsating device that accelerates orthodontic tooth movement by as much as 50 percent, also significantly reduces the pain associated with orthodontic treatment.

Photo - http://photos.prnewswire.com/prnh/20160321/346180

The peer-reviewed article published in the respected industry journal Angle Orthodontist, "Pain Control in Orthodontics Using a Micropulse Vibration Device: A Randomized Clinical Trial," shares the compelling results of how micropulse vibration, as used in AcceleDent, significantly lowers pain scores for overall pain during orthodontic treatment and biting pain.

The prospective, randomized controlled trial involved 58 orthodontic patients divided into an AcceleDent Group and a Control Group. Patients in both groups were directed not to take any pain medication or use topical ointments. The AcceleDent Group patients used their lightweight, hands-free pulsating device for the recommended 20 minutes per day and reported that they were in less pain throughout treatment than the patients who were in the Control Group. At a .05 significance level, a clear difference in overall pain for the AcceleDent Group versus the Control Group was detected (P= 0.002) and the same is true for the difference in biting pain between the two groups (P=0.003).

"We now have clinical proof to substantiate what patients have been telling us all along--that AcceleDent is the only technology that gives patients faster orthodontic treatment with less pain," said Michael K. Lowe, president and CEO of OrthoAccel® Technologies, Inc., which manufactures AcceleDent. "This randomized controlled trial was well-designed and the results are conclusive in further supporting why AcceleDent is the accelerated treatment solution preferred by the world's most respected orthodontists."

During the four-month study period, patients went to the orthodontist at the beginning of each month for adjustments and wire changes. Patients recorded incidence and severity of pain daily for the first seven days following the adjustment appointment and then weekly for the remainder of each month. Patients in the AcceleDent Group recorded pain scores within one hour of using the device.

"This study clearly demonstrates that, in addition to faster tooth movement, AcceleDent provides 'pure' pain management for orthodontic patients who frequently report discomfort during treatment," said Dr. Katie Graber of Graber Orthodontics. "I've found that patients and parents appreciate AcceleDent's reduction in discomfort because it eliminates the need for over-the-counter or prescription pain medication."

To read the peer-reviewed article, visit Angle Orthodontist.

About OrthoAccel® Technologies, Inc.

Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company engaged in the development, manufacturing and marketing of products to enhance dental care and orthodontic treatment. OrthoAccel developed and sells AcceleDent®, the first FDA-cleared clinical approach to safely accelerate orthodontic tooth movement by applying gentle micropulses via SoftPulse Technology® as a complement to existing orthodontic treatment. More information can be found at acceledent.com and acceledent.co.uk or requested via info@orthoaccel.com. Visit the company's Facebook page at Facebook.com/AcceleDent.

© 2016 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.